【Can-Fite BioPharma-Product CF101】Can-Fite BioPharma Receives Notice of Allowance From U.S. Patent and Trademark Office for Osteoarthritis Drug

Partner News

4th February 2019 – Can-Fite BioPharma
Limited issued an announcement, which is summarized as follows: :

BioPharma Limited announced that it has received a Notice of Allowance from the
U.S. Patent and Trademark Office for its patent application titled, “Use of A3
adenosine receptor agonist in the treatment of Osteoarthritis.” This
patent addresses methods for treating osteoarthritis with A3 adenosine receptor
(A3AR) agonists and has been granted to Can-Fite in major global markets
including North and South America, Europe and Asia.

“The notice
of allowance for this patent application is designed to secure Can-Fite’s
proprietary rights in a commercially very important and lucrative therapeutic
indication,” said Dr. Ilan Cohn, the Company’s Chairman “This new patent application
adds significant value to Can-Fite’s very extensive and valuable patent estate
and may provide the platform for developing Can-Fite’s proprietary A3AR
agonists for osteoarthritis, where there is a market need for efficacious and
safe drugs.”

The original
website link: